Our story MedDay was founded on the premise that neurodegenerative disorders can be treated by targeting key metabolic pathways. Read more
MD1003: high dose Pharmaceutical grade Biotin MedDay’s lead candidate, MD1003, is a patented oral formulation of high dose Pharmaceutical grade Biotin (hdPB). Development has been stopped after its second confirmatory Phase III study “SPI2” in Progressive Multiple Sclerosis did not meet its primary or secondary endpoints. Read more
Our pipeline Our pipeline currently comprises one lead candidate, MD1003, which has been developed into and through clinical trials, including two phase III studies in Progressive Multiple Sclerosis. Read more
For Patients and Families At MedDay, we are driven by patient needs and outcomes, placing people living with neurodegenerative conditions and their families at the heart of everything we do. Read more
